title: [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
abstract: Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), in advanced stage of disease, is resistant to standard chemotherapy. Imatinib was found to be effective in these patients. This paper shows our preliminary results. Imatinib mesylate was given to 15 patients during a 9-month period. Nine of them were in accelerated phase and 6 in blastic crisis of Ph+ CML. Patients were evaluated for hematologic and cytogenetic responses. Imatinib mesylate induced complete haematologic response in 12 patients (80% and cytogenetic response in 8 patients (53%). Six patients (40%) had a major cytogenetic response. After a 9-month follow up Ph+ CML progressed in 9 patients (60%) and 4 of them died. The most frequent adverse effects were edema, nausea, neutropenia and thrombocytopenia. Imatinib mesylate has a substantial, but short term activity in the accelerated phase and blastic crisis of the Ph+ CML.
authors.affiliation: Zavod za hematologiju, Klinika za unutrasnje bolesti Medicinskog fakulteta, Klinicki bolnicki centar, Kispatićeva 12, 10 000 Zagreb.
authors.forename: Josko
authors.initials: J
authors.lastname: Bulum
authors.forename: Boris
authors.initials: B
authors.lastname: Labar
authors.forename: Mirta
authors.initials: M
authors.lastname: Mikulić
authors.forename: Vinko
authors.initials: V
authors.lastname: Bogdanić
authors.forename: Dubravka
authors.initials: D
authors.lastname: Sertić
authors.forename: Damir
authors.initials: D
authors.lastname: Nemet
authors.forename: Velka
authors.initials: V
authors.lastname: Krecak-Gverić
authors.forename: Jasna
authors.initials: J
authors.lastname: Kovacević
authors.forename: Ranka
authors.initials: R
authors.lastname: Serventi-Seiwerth
authors.forename: Sanja
authors.initials: S
authors.lastname: Mrsić-Davidović
authors.forename: Renata
authors.initials: R
authors.lastname: Zadro
authors.forename: Dubravka
authors.initials: D
authors.lastname: Boban
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases